Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The endothelium is the orchestral conductor of blood vessel function. Pathological blood vessel formation (a process termed pathological angiogenesis) or the inability of endothelial cells ( EC s) to perform their physiological function (a condition known as EC dysfunction) are defining features of various diseases. Therapeutic intervention to inhibit aberrant angiogenesis or ameliorate EC dysfunction could be beneficial in diseases such as cancer and cardiovascular disease, respectively, but current strategies have limited efficacy. Based on recent findings that pathological angiogenesis and EC dysfunction are accompanied by EC ‐specific metabolic alterations, targeting EC metabolism is emerging as a novel therapeutic strategy. Here, we review recent progress in our understanding of how EC metabolism is altered in disease and discuss potential metabolic targets and strategies to reverse EC dysfunction and inhibit pathological angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 1×
“…function (a condition termed EC dysfunction) contributes to cardiovascular disease and diabetes (Davignon & Ganz, 2004), whereas diseases such as cancer and age-related macula degeneration are characterized by new blood vessel formation (a process termed angiogenesis) (Carmeliet & Jain, 2011).”
Self-citationOxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · cited 1×
“In addition, HMG-coA blockade also decreases geranyl-geranyl production, which reduces RhoA activity and restores a more beneficial eNOS/arginase balance (Goldstein & Brown, 1990; Liao & Laufs, 2005).”
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277 · cited 2×
“While the precise effects on mitochondrial respiration require further study, hyperglycemia-induced mitochondrial ROS induces DNA breaks and thereby activates polyAPD-ribose polymerase (PARP-1) (Du et al , 2000, 2003; Nishikawa et al , 2000; Giacco & Brownlee, 2010; Blake & Trounce, 2013).”
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2×
“…endothelial growth factor (VEGF) signaling) is the only clinically approved anti-angiogenic strategy, but the benefits are limited as tumors acquire resistance within months after treatment initiation (Bergers & Hanahan, 2008; Carme-liet & Jain, 2011; Ebos & Kerbel, 2011; Welti et al , 2013).”
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Self-citationTranscriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres
Lin, J., Wu, H., Tarr, P. T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., Isotani, E., Olson, E. N., et al. (2002) · Nature · doi:10.1038/nature00904 · Cited by 2,546 · cited 1×
“Hyperglycemia induces peroxisome proliferator-activated receptor-gamma coactivator 1a (PGC-1a), an important regulator of metabolic gene expression and mitochondrial biogenesis (Puigserver et al, 1998; Herzig et al, 2001; Lin et al, 2002).”
BackgroundRole of Endothelial Dysfunction in Atherosclerosis
Davignon, J., & Ganz, P. (2004) · Circulation · doi:10.1161/01.cir.0000131515.03336.f8 · Cited by 2,513 · cited 2×
“The inability of ECs to perform their physiological function (a condition termed EC dysfunction) contributes to cardiovascular disease and diabetes (Davignon & Ganz, 2004), whereas diseases such as cancer and age-related macula degeneration are characterized by new blood vessel formation (a process…”
Cited by
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
Gimbrone, M. A., & García-Cardeña, G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306301 · Cited by 3,476
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Metabolic Instruction of Immunity
Buck, M. D., Sowell, R. T., Kaech, S. M., & Pearce, E. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.004 · Cited by 1,214
Yang, E., Wang, X., Gong, Z., Yu, M., Wu, H., & Zhang, D. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00359-5 · Cited by 494
Yang, L., Achreja, A., Yeung, T.-L., Mangala, L. S., Jiang, D., Han, C., Baddour, J., Marini, J. C., Ni, J., Nakahara, R., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.011 · Cited by 429
Nixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400
TRPV4: molecular conductor of a diverse orchestra
White, J. P. M., Cibelli, M., Urban, L., Nilius, B., McGeown, J. G., & Nagy, I. (2016) · Physiological Reviews · doi:10.1152/physrev.00016.2015 · Cited by 405
ROS homeostasis and metabolism: a critical liaison for cancer therapy
Kim, J., Kim, J., & Bae, J.-S. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.119 · Cited by 293
Flow-induced reprogramming of endothelial cells in atherosclerosis
Tamargo, I. A., Baek, K. I., Kim, Y., Park, C., & Jo, H. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00883-1 · Cited by 286
Samuel, S. M., Ghosh, S., Majeed, Y., Arunachalam, G., Emara, M. M., Ding, H., & Triggle, C. R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.001 · Cited by 37
Mathews Samuel, S., Satheesh, N. J., Ghosh, S., Büsselberg, D., Majeed, Y., Ding, H., & Triggle, C. R. (2019) · Cancers · doi:10.3390/cancers11111737 · Cited by 28
“Although clinically approved and tested, pharmacological inhibition of VEGF has limited benefits as an anti-angiogenic therapeutic strategy in cancers since tumors are known to acquire resistance to a drug regimen that solely targets the VEGF pathway [23].”
BackgroundGlycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
Qusairy, Z., & Rada, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05303-1 · Cited by 16
Metadata
- Authors
- Goveia, J., Stapor, P., & Carmeliet, P.
- Venue
- EMBO Molecular Medicine
- Published
- 2014-07-25
- Volume
- 6
- Issue
- 9
- Pages
- 1105-1120
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2096823131
- Cited by
- 200
- References
- 38
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.